2-amino-N'-benzylideneacetohydrazides and derivatives for the management of CFTR protein mediated diseases

US11116736B2 · kind B2 · utility

Assignees

• EMORY UNIVERSITY · US
• Bar-Ilan University · IL
• Children's Healthcare of Atlanta · US

Inventors

• Nael McCarty · Atlanta, US
• Guiying Cui · Shelby Charter Township, US
• Hanoch Senderowitz · Nes Ziona, IL
• Netaly Khazanov · Petah Tikva, IL

Key dates

• Filing date: Jan 3, 2020
• Grant date: Sep 14, 2021
• Expiry date: Jan 3, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P11/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 2-amino-N′-benzylidene-acetohydrazide compound or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N′-benzylidene-acetohydrazide compound is ((E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide; or (E)-N′-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide.